Shots:

• The approval is based on efficacy data in two lethal orthopoxvirus animal models- i.e rabbitpox model & mousepox model evaluating Tembexa (100 mg- PO- tablets & 10 mg/mL oral suspension dosed- given once weekly for 2 wks.) vs PBO in adult & pediatric patients with Smallpox
• The studies for each model showed that the therapy resulted in significant survival- following delayed treatment after animals were infected with a lethal viral dose.
• Tembexa is the First smallpox antiviral approved for all age groups- including infants- and patients who have difficulty in swallowing. The therapy is being developed under an ongoing collaboration with BARDA

  Ref: Chimerix | Image: Chimerix